Reza Askari, MD
Trauma Surgery · Boston, MANPI 1063536944
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,807 of the $4,431 with a category attached, or 63.3%. 7 manufacturers reported payments, led by TELA Bio, Inc. at 43.7% of the total. Reporting peaked in 2023 at $2,047 and has fallen 78.9% since, to $433 in 2025.
Across 41 payments — averaging $108.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TELA Bio, Inc.$2K
- Davol Inc.$2K
- La Jolla Pharmaceutical Company$427
- Intuitive Surgical$138
- KCI USA, Inc.$119
- Bioventus LLC$83
- plus $45 from 1 others
What the payments were for
- Consulting fees$1,00023%
- Travel & lodging$62414%
- Food & beverage$2,80763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TELA Bio, Inc. | 18 | $1,934 |
| Davol Inc. | 14 | $1,685 |
| La Jolla Pharmaceutical Company | 5 | $427 |
| Intuitive Surgical | 1 | $138 |
| KCI USA, Inc. | 1 | $119 |
| Bioventus LLC | 1 | $83 |
| Covidien LP | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few trauma surgery providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CholestyramineCholestyramine (With Sugar) | 13 | $1,737 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $215 |
| Oxycodone Hcl | 22 | $129 |
| Neomycin Sulfate | 12 | $46 |
| Metronidazole | 12 | $17 |
Paid to pharmacies, not to this prescriber.
Other trauma surgery in Boston
- Benjamin JohnsonBoston$20K
- Charles ParsonsBoston$18K
- Geoffrey AndersonBoston$13K
- Martin RosenthalBoston$12K
- Michael DewaneBoston$2K
- John HwabejireBoston$1K
- Joanna EtraBoston$859
- George VelmahosBoston$456
- Michael SzymanskiBoston$129
- Sean HerseyFairhaven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.